
Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of PAS-004 In Adult NF1 Patients And Activation Of First ...
(MENAFN- GlobeNewsWire - Nasdaq) -- First patient expected to be dosed during Q2 2025 -- -- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas …